Item Type | Name |
Concept
|
Muscle Neoplasms
|
Concept
|
Esophageal Neoplasms
|
Concept
|
Brain Neoplasms
|
Concept
|
Lung Neoplasms
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Thymus Neoplasms
|
Concept
|
Lip Neoplasms
|
Concept
|
Ovarian Neoplasms
|
Concept
|
Nose Neoplasms
|
Concept
|
Colorectal Neoplasms
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Bone Neoplasms
|
Concept
|
Maxillary Sinus Neoplasms
|
Concept
|
Sebaceous Gland Neoplasms
|
Concept
|
Liver Neoplasms
|
Concept
|
Soft Tissue Neoplasms
|
Concept
|
Early Detection of Cancer
|
Concept
|
Pleural Neoplasms
|
Concept
|
Breast Neoplasms
|
Concept
|
Neoplasms
|
Concept
|
Skin Neoplasms
|
Concept
|
Colonic Neoplasms
|
Concept
|
Gastrointestinal Neoplasms
|
Concept
|
Cancer Survivors
|
Academic Article
|
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
|
Academic Article
|
Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors.
|
Academic Article
|
Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
|
Academic Article
|
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.
|
Academic Article
|
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
|
Academic Article
|
Precision medicine: lessons learned from the SHIVA trial.
|
Academic Article
|
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
|
Academic Article
|
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.
|
Academic Article
|
Doubling down with inhibitors of Notch and Hedgehog signaling pathways.
|
Academic Article
|
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report.
|
Academic Article
|
Pathway targets to explore in the treatment of non-small cell lung cancer.
|
Academic Article
|
Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
|
Academic Article
|
Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'.
|
Academic Article
|
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.
|
Academic Article
|
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.
|
Academic Article
|
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
|
Academic Article
|
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
|
Academic Article
|
Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer.
|
Academic Article
|
Tumor Mutation Burden-From Doubts to Concerns-In Reply.
|
Academic Article
|
TMB or not TMB as a biomarker: That is the question.
|
Academic Article
|
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
|
Academic Article
|
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges.
|
Academic Article
|
Influence of Robotic-Assisted Surgery on Readmission Burden.
|
Academic Article
|
Reviewing concomitant medications for participants in oncology clinical trials.
|
Academic Article
|
Pathway targets to explore in the treatment of small cell and large cell lung cancers.
|
Academic Article
|
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
|
Academic Article
|
Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
|
Academic Article
|
Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform.
|
Academic Article
|
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
|
Academic Article
|
STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.
|
Academic Article
|
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.
|
Academic Article
|
Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.
|
Academic Article
|
miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
|
Academic Article
|
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
|
Academic Article
|
Translating next-generation sequencing from clinical trials to clinical practice for the treatment of advanced cancers.
|
Academic Article
|
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
|
Academic Article
|
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
|
Academic Article
|
Using circulating cell-free DNA to monitor personalized cancer therapy.
|
Academic Article
|
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
|
Academic Article
|
Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.
|
Academic Article
|
A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy.
|
Academic Article
|
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
|
Academic Article
|
Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma.
|
Academic Article
|
Basal cell nevus syndrome: a brave new world.
|
Academic Article
|
From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
|
Academic Article
|
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration.
|
Academic Article
|
Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.
|
Academic Article
|
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
|
Academic Article
|
Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients.
|
Academic Article
|
The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review.
|
Academic Article
|
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
|
Academic Article
|
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs.
|
Academic Article
|
miRNAs in lung cancer: large roles for small players.
|
Academic Article
|
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
|
Academic Article
|
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
|
Academic Article
|
18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.
|
Academic Article
|
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
|
Academic Article
|
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
|
Academic Article
|
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
|
Academic Article
|
A retrospective matched cohort study evaluating the effects of percutaneous endoscopic gastrostomy feeding tubes on nutritional status and survival in patients with advanced gastroesophageal malignancies undergoing systemic anti-cancer therapy.
|
Academic Article
|
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
|
Academic Article
|
Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC).
|
Academic Article
|
Tumor Mutation Burden-From Hopes to Doubts.
|
Academic Article
|
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
|
Academic Article
|
Determinants of patient screen failures in Phase 1 clinical trials.
|
Academic Article
|
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
|
Academic Article
|
Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics.
|
Academic Article
|
Interpretation of PET scans: do not take SUVs at face value.
|
Academic Article
|
MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer.
|
Academic Article
|
Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.
|
Academic Article
|
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
|
Academic Article
|
Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer.
|
Academic Article
|
Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients.
|
Academic Article
|
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
|
Academic Article
|
Biomarkers associated with metastasis of lung cancer to brain predict patient survival.
|
Academic Article
|
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.
|
Academic Article
|
Thymic carcinoma: current and future therapeutic interventions.
|
Academic Article
|
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
|
Academic Article
|
Examining the effect of teleconferences on oncology phase 1 trials.
|
Academic Article
|
Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
|
Academic Article
|
Prophylactic cranial irradiation in small-cell lung cancer.
|
Academic Article
|
Molecular characterization may be of PARAMOUNT importance.
|
Academic Article
|
From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).
|
Academic Article
|
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer.
|
Academic Article
|
Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials.
|
Academic Article
|
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
|
Academic Article
|
A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
|
Academic Article
|
Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer.
|
Academic Article
|
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.
|
Academic Article
|
Targeting the Hedgehog and Notch signaling pathways.
|
Academic Article
|
A new era of treating advanced lung cancer is upon us.
|
Academic Article
|
Heavy Metal Content in Thoracic Tissue Samples from Patients with and without NSCLC.
|
Academic Article
|
Predictable modulation of cancer treatment outcomes by the gut microbiota.
|
Academic Article
|
Molecular determinants of lung cancer metastasis to the central nervous system.
|
Academic Article
|
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500?mg/m(2) every 21 days in patients with cancer.
|
Academic Article
|
Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.
|
Academic Article
|
Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic.
|
Academic Article
|
Long insert whole genome sequencing for copy number variant and translocation detection.
|
Academic Article
|
Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
|
Academic Article
|
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).
|
Academic Article
|
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
|
Academic Article
|
CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.
|
Academic Article
|
Measuring tumor mutation burden in cell-free DNA: advantages and limits.
|
Academic Article
|
Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.
|
Academic Article
|
The hedgehog knows many tricks.
|
Academic Article
|
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
|
Academic Article
|
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
|
Academic Article
|
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
|
Academic Article
|
FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.
|
Academic Article
|
No miR quirk: dysregulation of microRNAs in pancreatic ductal adenocarcinoma.
|
Academic Article
|
MicroRNAs and cancer: past, present, and potential future.
|
Academic Article
|
Yellowish, verrucous lesions on the scalp.
|
Academic Article
|
Basal cell carcinoma (BCC) causing spinal cord compression.
|
Academic Article
|
Total lower lip reconstruction with innervated muscle-bearing flaps: a modification of the Webster flap.
|
Academic Article
|
Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.
|
Academic Article
|
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status.
|
Academic Article
|
Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions.
|
Academic Article
|
Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer.
|
Academic Article
|
Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer.
|